Arbaclofen placarbil (/ɑːrˈbækloʊfɛnpləˈkɑːrbɪl/ar-BAK-loh-fen plə-KAR-bil, also known as XP19986) is a
prodrug of R-
baclofen. Arbaclofen placarbil possesses more favorable pharmacokinetic profile than baclofen, with less fluctuations in plasma drug levels. It was being developed as a potential treatment for patients with
GERD and spasticity due to
multiple sclerosis; however, in May 2013 XenoPort announced the termination of development because of unsuccessful results in
phase III clinical trials.[1]
It is being developed as an addiction medicine to treat alcoholism. [2] It is also studied as a potential therapeutic for some autistic subjects.[3]
Arbaclofen placarbil (/ɑːrˈbækloʊfɛnpləˈkɑːrbɪl/ar-BAK-loh-fen plə-KAR-bil, also known as XP19986) is a
prodrug of R-
baclofen. Arbaclofen placarbil possesses more favorable pharmacokinetic profile than baclofen, with less fluctuations in plasma drug levels. It was being developed as a potential treatment for patients with
GERD and spasticity due to
multiple sclerosis; however, in May 2013 XenoPort announced the termination of development because of unsuccessful results in
phase III clinical trials.[1]
It is being developed as an addiction medicine to treat alcoholism. [2] It is also studied as a potential therapeutic for some autistic subjects.[3]